All three major US stock indexes were up in late-morning trading on Monday, rebounding from losses in the previous session when the July jobs report was released.
In company news, Berkshire Hathaway (BRK.A, BRK.B) shares were down over 2% in recent Monday trading after the company said Saturday that its Q2 earnings fell to $8,601 per average equivalent class A share from $21,122 and revenue dropped to $92.52 billion from $93.65 billion a year earlier.
Tesla (TSLA) said it has awarded CEO Elon Musk 96 million new shares, adding that the shares only vest if he stays in a top executive role through 2027 and come with a five-year holding period, except for taxes or purchase costs.
The restricted stock's exercise price is $23.34 per share, upon vesting, the same as its exercise price per share of the 2018 CEO award. If the Delaware courts fully reinstate the 2018 CEO Performance Award, the new one will be voided or adjusted to prevent overlap, Tesla said.
Tesla sales of China-made electric vehicles declined 8.4% in July from a year earlier, pressured by competition from lower-priced new models, Reuters reported Monday, citing data from the China Passenger Car Association. The company did not immediately respond to requests for comment from MT Newswires.
Tesla shares were up more than 1% in recent Monday trading.
Amphenol (APH) and CommScope Holding's (COMM) shares were up over 3% and 74% respectively, after CommScope said it agreed to sell its connectivity and cable solutions business for $10.5 billion in cash in a deal expected to close in H1 2026.
IDEXX Laboratories (IDXX) shares were up 26% after the company posted stronger-than-expected Q2 earnings and revenue and boosted its 2025 guidance.
The company reported Q2 earnings Monday of $3.63 per diluted share, up from $2.44 a year earlier. Revenue for the quarter ended June 30 was $1.11 billion, compared with $1.00 billion a year earlier.
For 2025, IDEXX now expects earnings in the range of $12.40 to $12.76 per share, up from a prior guidance of $11.93 to $12.43, while revenue is projected to be between $4.21 billion and $4.28 billion, compared with a prior outlook of $4.10 billion to $4.21 billion.
BioNTech (BNTX) shares were up over 4% after the company said its Q2 loss narrowed to 1.60 euros ($1.85) per share from a loss of 3.36 euros and revenue rose to 260.8 million euros from 128.7 million euros a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.